Drug intelligence / Profile preview

ABBV-453 + daratumumab + lenalidomide + dexamethasone

Development stage: Unknown
Lead developer: AbbVie
Modality: MicroRNA (miRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
Administration: Oral, Subcutaneous, Intravenous

Overview

ABBV-453 + daratumumab + lenalidomide + dexamethasone is an investigational four-drug combination for the treatment of relapsed or refractory multiple myeloma. ABBV-453 is an orally available investigational small-molecule inhibitor being developed by AbbVie, while daratumumab is a monoclonal antibody targeting CD38, lenalidomide is an immunomodulatory agent, and dexamethasone is a synthetic corticosteroid. Together, they target malignant plasma cells via multiple pathways: ABBV-453 (mechanism details undisclosed), daratumumab (CD38 inhibition and immune activation), lenalidomide (modulation of immune function and inhibition of angiogenesis), and dexamethasone (anti-inflammatory and anti-myeloma effects). This combination is being studied for safety and preliminary efficacy in patients with multiple myeloma[3][7].

Other names: ABBV-453ABBV453ABBV 453daratumumablenalidomidedexamethasone

Targets

GR (Glucocorticoid receptor)CD38 (Cluster of Differentiation 38)CRBN (Cereblon)

Beyond the preview

Go deeper on ABBV-453 + daratumumab + lenalidomide + dexamethasone.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ABBV-453 + daratumumab + lenalidomide + dexamethasone.

Explore the full profile